Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

NCT04338243 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Negative T790M Mutation and Met Amplification

Interventions

DRUG: Glumetinib

Sponsor

Haihe Biopharma Co., Ltd.